BioSpace News Archive

A biosimilar medicine is developed to be highly similar to an existing biological, or reference, product.

MedCognetics, Inc., founded in early 2019, has developed an unbiased advanced imaging algorithm that leverages AI and Machine Learning (ML) to detect the earliest manifestations of cancer in all ethnicities, today announced it has received a $750,000 grant from the National Institute of Health’s (NIH) Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity, or AIM-AHEAD program.

Cellinfinity Bio today announced the publication of CLASH (CRISPR-based Library-scale AAV perturbation with Simultaneous HDR knock-in), a platform that for the first time enables massively parallel genomic knock-in into human cells.

Fzata, Inc., announces that it is raising series A funding for its first-in-class Bioengineered Probiotic Yeast Medicines platform.

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to initiate a first-in-human study of SC291 in patients with various B-cell malignancies.

Following extraordinary growth in 2020 and 2021, the life science group Sartorius again outperformed the market in fiscal 2022, achieving its targets for sales revenue and profitability.

Following extraordinary growth in 2020 and 2021, Sartorius Stedim Biotech, a leading partner of the biopharma industry, again outperformed the market in fiscal 2022.

SN BioScience and Boryeong signed a domestic manufacturing technology transfer and co-development contract for the albumin nanoparticle anticancer drug developed by SN BioScience for the first time in Korea and the fourth time in the world.

In the 2022 financial year, Novozymes delivers 9% organic sales growth – 11% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 26.4%, and ROIC including goodwill before special items* of 17.9%.

Net sales amounted to SEK 131.5 million (85.9), corresponding to an increase of 53 percent in SEK and 34 percent adjusted for currency effects. Organic growth accounted for 27 percent and acquired growth for 7 percent.